Ocaratuzumab

N/A

Report date: 2022/11/25 17:01:05

Base Information

Drug NameOcaratuzumab
Drug Alias Name奥卡妥珠单抗ocaratuzumabum奥卡妥组单抗AME-133vLY-2469298 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesApplied Molecular Evolution Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMentrik Biotech LlcApplied Molecular Evolution Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG